Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Mingzhu Zhang, Wujisiguleng Bao, Qiyan Zheng, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Effect of Avenciguat on Albuminuria in Patients with CKD
Hiddo J.L. Heerspink, David Cherney, Abdul Halim Abdul Gafor, et al.
Journal of the American Society of Nephrology (2024) Vol. 35, Iss. 9, pp. 1227-1239
Open Access | Times Cited: 15
Cardiovascular Efficacy and Safety of Finerenone: A Meta‐Analysis of Randomized Controlled Trials
Mushood Ahmed, Areeba Ahsan, Aimen Shafiq, et al.
Clinical Cardiology (2025) Vol. 48, Iss. 2
Open Access | Times Cited: 1
Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table
Francesco Cosentino, Subodh Verma, Philip Ambery, et al.
European Heart Journal (2023) Vol. 44, Iss. 39, pp. 4141-4156
Open Access | Times Cited: 18
MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials
Faı̈ez Zannad, Arun J. Sanyal, Javed Butler, et al.
Journal of Internal Medicine (2024) Vol. 296, Iss. 1, pp. 24-38
Open Access | Times Cited: 6
Outcomes With Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance
Thomas Ebert, Stefan D. Anker, Luís M. Ruilope, et al.
Diabetes Care (2023) Vol. 47, Iss. 3, pp. 362-370
Open Access | Times Cited: 14
The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes
Jessica Kearney, Luigi Gnudi
Pharmaceutics (2023) Vol. 15, Iss. 5, pp. 1343-1343
Open Access | Times Cited: 12
Low-Protein Diets, Malnutrition, and Bone Metabolism in Chronic Kidney Disease
Cidália Pereira, C. Guimarães, Vânia Ribeiro, et al.
Nutrients (2024) Vol. 16, Iss. 18, pp. 3098-3098
Open Access | Times Cited: 4
Efficacy and safety of finerenone in non-diabetic CKD patients: a single-center, real-world, retrospective study
Yu Li, Jiaxing Feng, Xiaodan Guo, et al.
Research Square (Research Square) (2025)
Closed Access
From past to present: tracing the trends of diabetes drug trials in mainland China
Zengqing Ma, Xin Zhao, Yu Lin, et al.
Frontiers in Endocrinology (2025) Vol. 15
Open Access
Finerenona no Tratamento da Nefropatia Diabética: Perspectivas Atuais e Evidências Clínicas
R. Schmidt, Luís Alberto Batista Peres, Alfredo Casagrande Laude
Cuadernos de Educación y Desarrollo (2025) Vol. 17, Iss. 3, pp. e7760-e7760
Closed Access
Role and application prospective of non-steroidal MRA in the treatment of diabetic kidney disease
Yuying Sun, Mingzhu Wang
International Urology and Nephrology (2025)
Closed Access
Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials
Jingyi Guo, Maoying Wei, Wen‐Hua Zhang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Primary Aldosteronism and the Role of Mineralocorticoid Receptor Antagonists for the Heart and Kidneys
Jordana B. Cohen, Irina Bancos, Jenifer M. Brown, et al.
Annual Review of Medicine (2022) Vol. 74, Iss. 1, pp. 217-230
Open Access | Times Cited: 18
Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis
Samit Ghosal, Binayak Sinha
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 7
Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China
Jingying Zhou, Le Kang, Chenjie Gu, et al.
Renal Failure (2024) Vol. 46, Iss. 2
Open Access | Times Cited: 2
Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: A systematic review and meta-analysis
Qi Chen, Yingnan Liang, Jiaxin Yan, et al.
Diabetes Research and Clinical Practice (2022) Vol. 195, pp. 110210-110210
Closed Access | Times Cited: 11
Multicentric Carpotarsal Osteolysis Syndrome Associated Nephropathy: Novel Variants of MAFB Gene and Literature Review
Stefania Drovandi, Francesca Lugani, Olivia Boyer, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 15, pp. 4423-4423
Open Access | Times Cited: 8
Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure
Jonathan D. Ravid, Luke J. Laffin
Current Cardiology Reports (2022) Vol. 24, Iss. 10, pp. 1251-1259
Closed Access | Times Cited: 8
Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone
Alberto Ortíz, Roberto Alcázar Arroyo, Pedro Pablo Casado Escribano, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 6, pp. 519-531
Closed Access | Times Cited: 3
Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis
Farah Yasmin, Muhammad Aamir, Hala Najeeb, et al.
Annals of Medicine and Surgery (2023) Vol. 85, Iss. 10, pp. 4973-4980
Open Access | Times Cited: 3
Recurrent Immunoglobulin A Nephropathy after Kidney Transplant—An Updated Review
Hwarang S. Han, Michelle Lubetzky, Nidharshan S. Anandasivam, et al.
Transplantology (2023) Vol. 4, Iss. 3, pp. 161-177
Open Access | Times Cited: 2
Finerenone: A Novel Drug Discovery for the Treatment of Chronic Kidney Disease
Akshita Rana, Jagdish K. Sahu
Current Drug Discovery Technologies (2024) Vol. 21, Iss. 6
Closed Access
Efficacy of Mineralocorticoid Receptor Antagonists on Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: An Umbrella Review
Porntep Amornritvanich, Thunyarat Anothaisintawee, John Attia, et al.
Kidney Medicine (2024) Vol. 7, Iss. 2, pp. 100943-100943
Closed Access
Finerenone (Kerendia)
CADTH
Canadian Journal of Health Technologies (2023) Vol. 3, Iss. 5
Open Access | Times Cited: 1
Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis
Samit Ghosal, Binayak Sinha
Research Square (Research Square) (2022)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top